Welcome to LookChem.com Sign In|Join Free
  • or
4-(1H-pyrazol-1-yl)-N-(quinolin-8-yl)benzenesulfonamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1232007-52-1

Post Buying Request

1232007-52-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1232007-52-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1232007-52-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,2,0,0 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1232007-52:
(9*1)+(8*2)+(7*3)+(6*2)+(5*0)+(4*0)+(3*7)+(2*5)+(1*2)=91
91 % 10 = 1
So 1232007-52-1 is a valid CAS Registry Number.

1232007-52-1Downstream Products

1232007-52-1Relevant academic research and scientific papers

Metal-Binding Pharmacophore Library Yields the Discovery of a Glyoxalase 1 Inhibitor

Perez, Christian,Barkley-Levenson, Amanda M.,Dick, Benjamin L.,Glatt, Peter F.,Martinez, Yadira,Siegel, Dionicio,Momper, Jeremiah D.,Palmer, Abraham A.,Cohen, Seth M.

supporting information, p. 1609 - 1625 (2019/02/14)

Anxiety and depression are common, highly comorbid psychiatric diseases that account for a large proportion of worldwide medical disability. Glyoxalase 1 (GLO1) has been identified as a possible target for the treatment of anxiety and depression. GLO1 is a Zn2+-dependent enzyme that isomerizes a hemithioacetal, formed from glutathione and methylglyoxal, to a lactic acid thioester. To develop active inhibitors of GLO1, fragment-based drug discovery was used to identify fragments that could serve as core scaffolds for lead development. After screening a focused library of metal-binding pharmacophores, 8-(methylsulfonylamino)quinoline (8-MSQ) was identified as a hit. Through computational modeling and synthetic elaboration, a potent GLO1 inhibitor was developed with a novel sulfonamide core pharmacophore. A lead compound was demonstrated to penetrate the blood-brain barrier, elevate levels of methylglyoxal in the brain, and reduce depression-like behavior in mice. These findings provide the basis for GLO1 inhibitors to treat depression and related psychiatric illnesses.

From sensors to silencers: Quinoline- and benzimidazole-sulfonamides as inhibitors for zinc proteases

Rouffet, Matthieu,De Oliveira, Cesar Augusto F.,Udi, Yael,Agrawal, Arpita,Sagi, Irit,McCammon, J. Andrew,Cohen, Seth M.

supporting information; experimental part, p. 8232 - 8233 (2010/08/05)

Derived from the extensive work in the area of small molecule zinc(II) ion sensors, chelating fragment libraries of quinoline- and benzimidazole- sulfonamides have been prepared and screened against several different zinc(II)-dependent matrix metalloproteinases (MMPs). The fragments show impressive inhibition of these metalloenzymes and preferences for different MMPs based on the nature of the chelating group. The findings show that focused chelator libraries are a powerful strategy for the discovery of lead fragments for metalloprotein inhibition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1232007-52-1